Cargando…
First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease
The combination of rifamycin (RFP), ethambutol (EB), and macrolides is currently the standard regimen for treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). However, poor adherence to the standardized regimens recommended by current guidelines have been reported. We undertook a sin...
Autores principales: | Fukushima, Kiyoharu, Kitada, Seigo, Komukai, Sho, Kuge, Tomoki, Matsuki, Takanori, Kagawa, Hiroyuki, Tsujino, Kazuyuki, Miki, Mari, Miki, Keisuke, Kida, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807086/ https://www.ncbi.nlm.nih.gov/pubmed/33441977 http://dx.doi.org/10.1038/s41598-021-81025-w |
Ejemplares similares
-
Long-Term Treatment Outcome of Progressive Mycobacterium avium Complex Pulmonary Disease
por: Fukushima, Kiyoharu, et al.
Publicado: (2020) -
Pleuroparenchymal fibroelastosis in Mycobacterium avium complex pulmonary disease: clinical characteristics and prognostic impact
por: Yamamoto, Yuji, et al.
Publicado: (2021) -
Evaluation of disease severity in bronchiectasis using impulse oscillometry
por: Yamamoto, Yuji, et al.
Publicado: (2020) -
Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease: a retrospective cohort study
por: Oshitani, Yohei, et al.
Publicado: (2020) -
Pulmonary disease caused by a newly identified mycobacterium: Mycolicibacterium toneyamachuris: a case report
por: Kuge, Tomoki, et al.
Publicado: (2020)